Spyre Therapeutics Inc. (SYRE) - Total Liabilities
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has total liabilities worth $93.14 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Spyre Therapeutics Inc. to track the company's year-over-year net asset growth rate.
Spyre Therapeutics Inc. - Total Liabilities Trend (2013–2025)
This chart illustrates how Spyre Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Spyre Therapeutics Inc. (SYRE) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Spyre Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Spyre Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avanza Bank Holding AB (publ)
ST:AZA
|
Sweden | Skr409.12 Billion |
|
Unicaja Banco SA
MC:UNI
|
Spain | €91.34 Billion |
|
D-Wave Quantum Inc.
NYSE:QBTS
|
USA | $75.56 Million |
|
GUOTAI JUNAN SEC. H YC1
F:153A
|
Germany | €1.91 Trillion |
|
KION GROUP AG ADRS/1/4
F:KGX1
|
Germany | €12.55 Billion |
|
The Hanover Insurance Group Inc
NYSE:THG
|
USA | $12.96 Billion |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
Denmark | Dkr74.74 Billion |
|
Dosilicon Co Ltd
SHG:688110
|
China | CN¥252.69 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Spyre Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Spyre Therapeutics Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spyre Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spyre Therapeutics Inc. (2013–2025)
The table below shows the annual total liabilities of Spyre Therapeutics Inc. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.55 Million | -31.03% |
| 2024-12-31 | $90.68 Million | -42.55% |
| 2023-12-31 | $157.84 Million | +657.44% |
| 2022-12-31 | $20.84 Million | -19.80% |
| 2021-12-31 | $25.98 Million | +19.27% |
| 2020-12-31 | $21.79 Million | -5.70% |
| 2019-12-31 | $23.10 Million | +124.05% |
| 2018-12-31 | $10.31 Million | +79.63% |
| 2017-12-31 | $5.74 Million | +40.10% |
| 2016-12-31 | $4.10 Million | +60.67% |
| 2015-12-31 | $2.55 Million | +141.02% |
| 2014-12-31 | $1.06 Million | -25.07% |
| 2013-12-31 | $1.41 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more